Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety-Reference-Cited by-同舟云学术

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

Published:2019-01-24 Issue:3 Volume:8 Page:281-289
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Lee Edward¹,Gibbs John P.¹,Emery Maurice G.¹,Block Geoffrey²,Wasserman Scott M.¹,Hamilton Lisa³,Kasichayanula Sreeneeranj¹,Hanafin Patrick¹,Somaratne Ransi¹,Egbuna Ogo¹

Affiliation:

1. Amgen Inc. Thousand Oaks CA USA

2. Denver Nephrology Research Division Denver CO USA

3. Amgen Ltd. Uxbridge United Kingdom

Funder

Amgen

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.650

Reference19 articles.

1. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction

2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy

3. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

4. Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

5. AMG145;Stein E WS;Drug Future,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy;Current Atherosclerosis Reports;2024-01-30

2. Novel therapeutic approaches in the management of chronic kidney disease: a narrative review;Postgraduate Medicine;2023-07-06

3. Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach—Where Do We Stand?;Journal of Clinical Medicine;2023-04-18

4. Choosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologist;Journal of Nephrology;2022-12-06

5. Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?;SN Comprehensive Clinical Medicine;2022-07-12